Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : LakePharma will manufacture commercial quantities of Akston’s adjuvated COVID-19 vaccine candidate (AKS-452), which is scheduled to begin Phase 1/2 clinical testing later this month.
Brand Name : AKS-452
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 05, 2021
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Akston Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?